In consultation: Guidance and quality standards

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Consultation end date

Consultation end date

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 1 to 5 of 5

TitleConsultationTypeConsultation end date
Dupilumab for treating moderate to severe chronic obstructive pulmonary disease ID6235Draft guidanceTechnology appraisal guidance
Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer [ID6153]Draft guidanceTechnology appraisal guidance
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (Review of TA909) [ID6434]Draft guidanceTechnology appraisal guidance
Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable [ID6332]Draft guidanceTechnology appraisal guidance
Fezolinetant for treating vasomotor symptoms associated with the menopause [ID5071]Draft guidanceTechnology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All